The purpose of this study was to investigate the main bioenergetics and neuromuscular determinants of the time to exhaustion (T(lim)) at the velocity corresponding to maximal oxygen uptake in recreational long-distance runners. Twenty runners performed the following tests on 5 different days: (a) maximal incremental treadmill test, (b) 2 submaximal tests to determine running economy and vertical stiffness, (c) exhaustive test to measured the T(lim), (d) maximum dynamic strength test, and (e) muscle power production test. Aerobic and anaerobic energy contributions during the T(lim) test were also estimated. The stepwise multiple regression method selected 3 independent variables to explain T(lim) variance. Total energy production explained 84.1% of the shared variance (p = 0.001), whereas peak oxygen uptake (V(O2)peak) measured during T(lim)and lower limb muscle power ability accounted for the additional 10% of the shared variance (p = 0.014). These data suggest that the total energy production, V(O2)peak, and lower limb muscle power ability are the main physiological and neuromuscular determinants of T(lim)in recreational long-distance runners.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1519/JSC.0b013e31823b8721 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of strength, endurance and lung function in subjects with neuromuscular diseases with the R577X polymorphism of the ACTN3 gene.
Andes Pediatr
August 2023
Departamento de Kinesiología, Facultad de Ciencias de la Salud, Universidad Católica del Maule, Talca, Chile.
Unlabelled: The ACTN3 R577X polymorphism determines the expression of alpha-actinin 3 protein in human muscle. The homozygous XX genotype fails to synthesize alpha-actinin 3 and is associated with lower muscle strength than the RR genotype. Neuromuscular diseases (NMD) generate an accelerated loss of muscle strength, and their relationship with the ACTN3 gene has not been established.
View Article and Find Full Text PDFExamining PACU Nurse Knowledge and Confidence of Neuromuscular Blocking Drugs and Neuromuscular Blocking Reversal Agents.
J Perianesth Nurs
January 2025
Ellmer School of Nursing Mason and Joan Brock Virginia Health Sciences, Old Dominion University, Virginia Beach, VA. Electronic address:
Purpose: neuromuscular blockade (NMB) remains a significant risk for patients after anesthesia. This study examines the confidence and knowledge of the use and side effects of NMB and associated reversal agents amongst postanesthesia care unit (PACU) nurses caring for the postanesthesia surgical population. Retrospective data on the incidence and demographics of patients who underwent general anesthesia with NMB were also examined.
View Article and Find Full Text PDF-Related Muscular Dystrophies, LGMD, and TMD, in an Estonian Family Caused by the Finnish Founder Variant.
Neurol Genet
December 2024
From the The Institute of Clinical Medicine (K.Õ., T.R., E.Õ.-S., L.M., S. Pajusalu), Faculty of Medicine, University of Tartu; Genetics and Personalized Medicine Clinic (K.Õ., T.R., L.M., Sander Pajusalu); Children's Clinic (E.O.-S.); Pathology Department (S. Puusepp), Tartu University Hospital, Estonia; Folkhalsan Research Center (M.S., B.U.), Helsinki; and Tampere Neuromuscular Center (B.U.), Tampere, Finland.
Background And Objectives: Tibial muscular dystrophy (TMD) is an autosomal dominant, slowly progressive late-onset distal myopathy. TMD was first described in 1991 by Udd et al. in Finnish patients, who were later found to harbor a heterozygous unique 11-bp insertion/deletion in the last exon of the gene-the Finnish founder variant (FINmaj).
View Article and Find Full Text PDFIntroduction: Living with a chronic disease impacts many aspects of life, including the ability to participate in activities that enable interactions with others in society, that is, social participation (SP). Despite efforts to monitor the quality of care and life of chronically ill people in Belgium, no disease-specific patient-reported measures (PRMs) have been used. These tools are essential to understand SP and to develop evidence-based recommendations to support its improvement.
View Article and Find Full Text PDFEpidemiology, management and patient needs in myasthenia gravis: an Italian multistakeholder consensus based on Delphi methodology.
BMJ Open
December 2024
Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Objectives: To provide comprehensive information on the burden of myasthenia gravis (MG) in Italy, including the unmet needs of patients and several other aspects related to the disease, based on skilled viewpoints of MG experts.
Design: Iterative analysis conducted in accordance with the best practices of the Delphi method, including anonymity, controlled feedback, and statistical stability of consensus.
Setting And Participants: 24 clinicians, 18 public health experts and 4 patient associations experts completed all the Delphi iterations between 18 April and 3 July 2023, for a total of 46 participants from several Italian Regions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!